Tandem Diabetes Care (TNDM) stock gains and Insulet (PODD) slips as Stifel changes their ratings, citing the market trends for tubeless insulin pumps. Read more here.
Insulet is undervalued, trading at a sub-median multiple despite 20% revenue growth and expanding margins. Learn more about PODD stock here.
Insulet Corp (PODD) delivered nearly 20% revenue growth with 490 basis points of operating margin expansion, while guiding 2027 growth modestly below mid-teens amid new competition.
While the top- and bottom-line numbers for Insulet (PODD) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
(PODD) on Wednesday reported third-quarter net income of $141.The Acton, Massachusetts-based company said it had net income of $2.
Insulet (NASDAQ:PODD) released second-quarter financial results and hosted an earnings call on Wednesday. Read the complete transcript below. This content is powered by Benzinga APIs. For comprehensive financial data
Detailed price information for General Motors Company (GM-N) from The Globe and Mail including charting and trades.
ACTON, Mass., October 01, 2026--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it will report financial results for the third quarter of 2026 on Wednesday, November 4, 2026, before the opening of the financial markets. In connection with the release, management will host a conference call that day at 8:00 a.m. (Eastern Time).
Insulet (PODD) sees emerging headwinds from new market entrants in 2027 and 2028, with the debate ar
Insulet has seen its share price fall hard over the past year, which puts the focus squarely on whether the current market value still lines up with the cash the business is expected to generate. With the stock under pressure, the key issue now is how its cash flows compare with the price investors are paying today. Over the past 12 months, Insulet shares have declined 57.2%. This puts a lot of weight on whether the business can support the present valuation through its future cash...
Insulet (PODD) recently reworked its financing by replacing $475 million of term loans with new debt at lower interest margins and expanding its revolving credit facility, a move that directly reshapes the balance sheet. Insulet’s refinancing lands after a tough stretch for the stock, with the share price down 52% year to date and the 1 year total shareholder return declining 58%. This points to fading momentum even before its recent index removal and conference appearances. Scan beyond...
This is the newest page. Registered accounts read further back.